Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies

Daniel K. Kajdasz, Smriti Iyengar, Durisala Desaiah, Misha Miroslav Backonja, John T. Farrar, David A. Fishbain, Troels S. Jensen, Michael C. Rowbotham, Christine N. Sang, Dan Ziegler, Henry J. McQuay

Research output: Contribution to journalArticlepeer-review

99 Scopus citations

Abstract

Objective: This post hoc analysis was aimed to summarize the efficacy and tolerability of duloxetine as represented by number needed to treat (NNT) and number needed to harm (NNH) to provide a clinically useful assessment of the position of duloxetine among current agents used to treat diabetic peripheral neuropathic pain (DPNP). Methods: Data were pooled from three 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in which patients received 60 mg duloxetine either QD or BID or placebo. NNT was calculated based on rates of response (defined as ≥30% and ≥50% reductions from baseline in the weekly mean of the 24-hour average pain severity scores); NNH was calculated based on rates of discontinuation due to adverse events (AEs). Results: Patients receiving duloxetine 60 mg QD and 60 mg BID had NNTs (95% CI) of 5.2 (3.8-8.3) and 4.9 (3.6-7.6), respectively, based on last observation carried forward; NNTs of 5.3 (3.8-8.3) for 60 mg QD and 5.7 (4.1-9.7) for 60 mg BID were obtained based on baseline observations carried forward. The NNHs (95% CI) based on discontinuation due to AEs were 17.5 (10.2-58.8) in the duloxetine 60-mg QD group and 8.8 (6.3-14.7) in the 60-mg BID group. Conclusion: These post hoc results suggest that duloxetine was effective and well tolerated for the management of DPNP and further support the importance of duloxetine as a treatment option for clinicians and patients to assist with the management of DPNP.

Original languageEnglish (US)
Pages (from-to)2536-2546
Number of pages11
JournalClinical Therapeutics
Volume29
Issue number11 SUPPL. 1
DOIs
StatePublished - Dec 28 2007

Keywords

  • diabetic peripheral neuropathic pain
  • duloxetine
  • neuropathy
  • NNH
  • NNT

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies'. Together they form a unique fingerprint.

Cite this